Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care

J Card Fail. 2022 Jun;28(6):991-1015. doi: 10.1016/j.cardfail.2021.11.006. Epub 2021 Nov 10.

Abstract

Cardiac implantable electronic devices, including implantable cardioverter-defibrillators and therapy, are part of guideline-indicated treatment for a subset of patients with heart failure with reduced ejection fraction. Current technological advancements in cardiac implantable electronic devices have allowed the detection of specific physiological parameters that are used to forecast clinical decompensation through algorithmic, multiparameter remote monitoring. Other recent emerging technologies, including cardiac contractility modulation and baroreflex activation therapy, may provide symptomatic or physiological benefits in patients without indications for cardiac resynchronization. Our goal in this state-of-the-art review is to describe the new commercially available technologies, their purported mechanisms of action, and the evidence surrounding their clinical roles, limitations and future directions. Finally, we underline the need for standardized workflow and close interdisciplinary management of this population to ensure the delivery of high-quality care.

Keywords: Remote monitoring; cardiac implantable electronic devices.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiac Resynchronization Therapy Devices
  • Cardiac Resynchronization Therapy*
  • Defibrillators, Implantable*
  • Electrophysiology
  • Heart Failure* / therapy
  • Humans
  • Technology

Grants and funding